TNGX

Tango Therapeutics (TNGX) to Benefit From Vopimetostat + KRAS Inhibitors Combined Revenues

Tango Therapeutics Rides a New Precision Oncology Trend in 2026

TNGX Stock Outlook Hinges on Vopimetostat and Key 2026 Catalysts

Is TNGX Stock Still Worth Buying After Its Huge Rally in 2026?

Enterprise value to EBITDA forward of Tango Therapeutics, Inc. – NASDAQ:TNGX

Enterprise value to EBIT forward of Tango Therapeutics, Inc. – NASDAQ:TNGX

Jefferies upgrades Tango Therapeutics stock rating on cancer trial data

Price to sales forward of Tango Therapeutics, Inc. – NASDAQ:TNGX

Tango Therapeutics stock hits all-time high at 33.19 USD

Tango Therapeutics Prices $566.5 Million Equity Offering at $30 Per Share; 30-Day Option Granted

Tango Therapeutics stock price target raised to $66 by H.C. Wainwright on trial data

Tango Therapeutics prices $600 million stock offering

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

Tango Therapeutics: Combo Data With Revolution's RAS Inhibitor Whets Risk Appetite (TNGX)

TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results